Tibotec Pharmaceuticals' protease inhibitor darunavir [PREZISTA] has received conditional marketing authorisation from the European Commission

Source: Inpharma, Volume 1, Number 1576, 2007-02-24 , pp. 23-23(1)

Publisher: Adis International

Key:
Free Content - Free Content
New Content - New Content
Subscribed Content - Subscribed Content
Free Trial Content - Free Trial Content

Keywords: Darunavir, therapeutic use; Development-status; HIV-1-infections, treatment; Research-and-development; Tibotec-Pharmaceuticals

Document Type: Short communication

The full text electronic article is available for purchase. You will be able to download the full text electronic article after payment.

$37.95 plus tax      Refund Policy

 

OR

Back to top

Key:
Free Content - Free Content
New Content - New Content
Subscribed Content - Subscribed Content
Free Trial Content - Free Trial Content
Share this item with others: These icons link to social bookmarking sites where readers can share and discover new web pages.
Page Help Click here for Page Help
Shopping cart
Tools
Sign in






Need to register?
Sign up here
Text size: A | A | A | A